IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC

NCT04945421 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

NPC

Interventions

DRUG: Sintilimab
DRUG: IBI310

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.